Here is what the page “Gilead to Pay $45 Million to Settle Texas Medicaid Kickback Charges” contains. Gilead Sciences has agreed to pay $45 million to resolve allegations that it paid kickbacks to improperly influence prescriptions covered by the Texas Medicaid program, according to the Texas attorney general. The settlement addresses claims that the pharmaceutical company violated state and federal anti-kickback laws by providing financial incentives to healthcare providers or other parties to boost prescriptions of its drugs. This case highlights ongoing scrutiny of pharmaceutical marketing practices and their impact on public healthcare programs.
The $45 million payment underscores the legal and financial risks companies face when accused of improper promotional activities. The settlement is a significant development for Texas Medicaid, which serves millions of low-income residents, and signals continued enforcement against healthcare fraud. Gilead, known for HIV and hepatitis C treatments, did not admit liability as part of the agreement. The full version stays on the original page, which this listing opens directly.